Sudan Seeks Indian Capital for Pharma Rebuild, Already 51% Imports

Sudan's Ambassador to India, Mohammed Abdalla Ali Eltom, on July 11, 2026, made a forceful case for deeper Indian pharmaceutical and healthcare investment, revealing that Indian medicines already command more than 51% of the country's total drug imports. The remarks came during a high-profile roundtable in New Delhi, co-organized by the Embassy of Sudan and the India & Arab Countries Chamber of Commerce, Industry & Agriculture (IACCIA). The event brought together unnamed but 'leading Indian pharmaceutical companies' alongside virtual participation from Sudan's drug regulator, the National Board of Pharmaceuticals and Poisons, and private-sector representatives. This marks a strategic pivot from a buyer-seller relationship to a partnership aimed at direct investment in manufacturing, distribution, and health infrastructure. The push comes as Sudan emerges from a devastating civil war that crippled its healthcare system. Waiel Awwad, Secretary General (In-charge) of IACCIA, noted that pharmaceuticals and healthcare were chosen as the priority sectors precisely because of the war's toll: the immediate need for medicines, medical equipment, and rebuilt facilities is enormous. By prioritizing these sectors, Sudan signals it is open for business and seeking foreign direct investment to reconstruct what conflict destroyed. India, often called the 'pharmacy of the developing world,' already enjoys significant trust and price advantage in Sudan. The 51% import share is a testament to the quality and affordability of Indian generics, including anti-infectives, cardiovascular drugs, and essential medicines. Transforming this trade dominance into on-the-ground investment could involve setting up local manufacturing plants, formulation units, and even research collaborations. For Indian pharmaceutical exporters, this is a chance to capture greater value and mitigate logistics and currency risks by producing closer to the end user. Sudan's regulator, the National Board of Pharmaceuticals and Poisons, participating virtually, is a crucial signal. Its presence suggests a willingness to streamline product registration and align with Indian pharmacopeial standards, which could accelerate market entry. For healthcare investors, the opportunity extends beyond drugs to hospital construction, diagnostic labs, telemedicine networks, and health IT systems—all desperately needed in a post-conflict setting. However, the environment is fraught with risk. Sudan's political stability remains fragile, and the economic aftermath of war includes currency volatility, damaged infrastructure, and weak purchasing power. While the roundtable was a confidence-building exercise, no specific investment commitments were announced, and it remains to be seen whether companies will act on the invitation. Indian pharma's presence in Africa is already substantial, and many firms have experience navigating similar frontier markets, but Sudan's unique challenges will require careful due diligence and likely government-backed guarantees. Looking ahead, the IACCIA's focus on pharma as the lead sector suggests that this roundtable is just the opening move. Future trade missions, bilateral investment treaties, and incentives packages may follow. If successful, Sudan could reduce its dependence on imports, build local employment, and improve health outcomes, while Indian companies gain a strategic foothold in a recovering economy. The next steps—formal company visits, feasibility studies, and pilot projects—will determine whether the 51% import figure becomes the foundation for a much larger economic partnership.